Mon, Jul 14, 2014, 2:11 AM EDT - U.S. Markets open in 7 hrs 19 mins

Recent

% | $
Quotes you view appear here for quick access.

NanoLogix Inc. Message Board

  • phloam131314 phloam131314 Dec 17, 2012 12:08 AM Flag

    12/17/2012 Press Release

    NanoLogix Rapid TB Detection Results Published In Journal of Microbial & Biochemical Technology
    Major Third-party R&D lab achieves 5-day Tuberculosis detection, compared to weeks for standard tests

    HUBBARD, Ohio, Dec 17, 2012 (BUSINESS WIRE) -- NanoLogix (otc markets:NNLX)

    An independent third-party study by one of the foremost Biomedical Research centers in the U.S. has demonstrated that NanoLogix's BioNanoPore (BNP) Ultra-Fast Identification Technology enables detection of live Tuberculosis cultures in five days as opposed to two+ weeks with traditional methods.

    The peer reviewed study appears in the online edition of the Journal of Microbial & Biochemical Technology.

    omicsonlineDOTorg/1948-5948/pdfdownload.php?download=JMBT-04-147.pdf&&aid=10157

    The authors conclude: "Ideally, highly accurate diagnostic tests for TB would be simple to perform, not require specialized equipment or facilities, provide rapid results for decreased time to treatment, are readily available, and cost-effective for the end user. These qualities are especially important in developing or high-TB burdened countries where the access and ability to purchase specialized equipment is limited, and number of trained personnel is low. The results of the present study demonstrate a proof-of-principal for BNP(TM) Middlebrook in detecting TB compared to the Middlebrook 7H10 reference test and should be considered as an ideal candidate for future evaluation of clinical samples."

    Current rapid detection methods using PCR (molecular diagnostic) technology have a number of limitations in the fight against TB. They are unable to differentiate between live actual infection, and presence of dead bacteria in immune patients. Furthermore, PCR technology is very expensive, and needs specially trained personnel to perform testing, something not available, or even feasible, in the areas of the world most in need. Furthermore, even with PCR, the standard still requires culture positivity, which currently is a 3-4 week process. In addition, drug sensitivity is equally as important as identification, and early results using our BNF technology are extremely encouraging, taking only a few hours after bacterial identification.

    Potential for the use of BNP technology is vast, said Bret T. Barnhizer, CEO of NanoLogix. "In addition to BNP's use in detecting many other bacteria, we see this technology as potentially providing both a standalone method for determining the presence of an actual TB infection and also a complementary method that can be used with either our BioNanoFilter (BNF) technology or molecular diagnostics methods for initial TB screening. We hope that our BNP rapid culture results will make it possible to finally monitor antibiotic treatment for TB in a close-to-real-time manner that is currently unavailable to practitioners. This ability could provide major assistance in the ongoing campaign to combat the scourge of Tuberculosis. We are committed to helping wipe out this horrible disease that takes over one million lives a year. As a partner in the Stop TB Alliance, we look forward to working further with them and WHO officials in a real effort to eradicate TB."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
NNLX
0.13+0.02(+18.07%)Jul 11 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.